OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Munshi on Testing for MRD in Multiple Myeloma

March 21st 2020

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.

Dr. Kumar on Ongoing Research in Multiple Myeloma

March 21st 2020

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses ongoing research in multiple myeloma.

Dr. Armstrong on Detection of Chromosomal Defects in mCRPC

March 21st 2020

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Dr. Tzachanis on Research Regarding Post-CAR T-Cell Therapy Progression in Lymphoma

March 20th 2020

Dimitrios Tzachanis, MD, PhD, discusses research regarding post–CAR T-cell therapy progression in lymphoma.

Dr. Iyer on Investigational FGFR Inhibitors in Metastatic Urothelial Carcinoma

March 20th 2020

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

Dr. Saint Fleur-Lominy on the Role of Transplant in MPNs

March 20th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Dr. Hamid on the Exploration of Predictive Biomarkers in mHSPC Subtypes

March 20th 2020

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

Dr. Armstrong on the Utility of AR-V7 as a Biomarker in Prostate Cancer

March 20th 2020

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.

Dr. Mizrahi on the Goal of the COMMIT Trial in dMMR Metastatic CRC

March 20th 2020

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Dr. Brufsky on Case Ascertainment Bias With COVID-19

March 20th 2020

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

Dr. Hillengass on Imaging Modalities in Multiple Myeloma

March 20th 2020

Jens Hillengass, MD, discusses available imaging modalities in multiple myeloma.

Dr. Otterson on Targetable Biomarkers in Lung Cancer

March 20th 2020

Gregory A. Otterson, MD, discusses targetable biomarkers in non–small cell lung cancer.

Dr. Hari on Misconceptions Regarding Allogeneic Stem Cell Transplant in Multiple Myeloma

March 19th 2020

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

Dr. Sholl on Challenges With Using Tissue Biopsy for Biomarker Testing in Lung Cancer

March 19th 2020

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Dr. Hamdan on the Potential Use of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

March 19th 2020

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer

March 19th 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

Dr. Gerds on Design and Safety Analysis of a Trial With Luspatercept in Myelofibrosis

March 19th 2020

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the design and safety analysis of a phase II trial of luspatercept in patients with myelofibrosis-associated anemia.

Dr. Borgen on Unanswered Questions With COVID-19

March 19th 2020

Patrick I. Borgen, MD, discusses what is currently known about coronavirus 2019 and unanswered questions that still need to be addressed.

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

March 19th 2020

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Dr. Goodman on the Role of PD-1 Inhibitors in T-Cell Lymphomas

March 19th 2020

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.